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Understanding the underlying mechanisms behind specific cancer types and other hereditary 
diseases is valuable not only for preventing and treating particular syndromes of interest, but also for 
adding general knowledge about cancer-promoting mutations overall. Considerable effort has been 
spent on sequencing the human genome to study how the order of nucleotides (As, Cs, Gs, and Ts) 
in our DNA code influences the likelihood of developing such inherited syndromes, but even if 
seemingly important individual mutations can be identified it is not always clear what part they play. 
Thus, combining specific case studies with general sequencing approaches informs our 
understanding of mutations that drive the malignant transformation. This premise was confirmed 
through a joint research effort undertaken by Fred Hutch scientists and external collaborators, led by 
the Clinical Research Division's Dr. Akiko Shimamura. The team studied a new hereditary syndrome 
featuring low blood platelet counts (thrombocytopenia) and a predisposition for various hematologic 
malignancies in multiple individuals from three families, with the aim of identifying common 
mutations. First-authored by a graduate student in the MD PhD program, Michael Zhang from the 
Shimamura Lab, their enlightening results were recently published in Nature Genetics. 
Through exome sequencing studies of a family of German and Native American ancestry with 
genetically undefined familial thrombocytopenia and cancer predisposition, the investigators 
identified a heterozygous hereditary variant in the ETV6 gene. "Heterozygous" signifies that only one 
of the two gene copies, coming from either the mother or the father, in a particular individual is 
mutated, as opposed to homozygous mutations which affect both gene copies. Targeted sequencing 
of individuals displaying similar disease characteristics (thrombocytopenia and hematologic 
malignancies) identified two additional families with germline heterozygous ETV6 mutations. These 
two families, of Scottish and African-American ancestry, respectively, each had a different 
hereditary ETV6 variant. 
These familial genetic studies suggest a vital role for the gene ETV6 in the formation, development 
and differentiation of blood cells, as well as in the promotion of malignancy. ETV6 encodes a protein 
that regulates expression of other genes, and the Shimamura lab demonstrated that 
this ETV6 function is impaired by mutations. The pinpointed gene was not an unknown player; large-
scale cancer genome sequencing efforts had previously demonstrated recurrent evidence for a  
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potential role of somatic ETV6mutations in cancer, but whether ETV6 played an active role in 
malignant transformation had not previously been demonstrated. 
Dr. Shimamura elegantly summed up the new findings in three succinct sentences: "Acquired 
mutations in ETV6 were previously observed in cancers arising in the general population. Our study 
demonstrates that ETV6 mutations function to initiate or drive cancer development. Thus, the study 
of rare cancer predisposition syndromes advances our understanding of molecular pathways 
promoting cancer development in the general population." 
Besides increasing the fundamental understanding of driving forces behind cancer progression, 
identifying hereditary mutations improves diagnosis and medical care of individuals at risk. "The 
elucidation of genes driving malignancy is critical to our ongoing efforts to develop personalized 
approaches to the diagnosis and treatment of cancer in individual patients. Identification of genetic 
causes of cancer predisposition allows appropriate medical monitoring to initiate treatments early 
when therapies are most effective," said Dr. Shimamura, who also emphasized that genetic testing is 
helpful for making informed therapy choices and guiding donor selection for bone marrow 
transplants. 
Thus, the circle is closed; from defining a rare familial syndrome to understanding disease 
progression in the general population, and then back to personalized treatments for affected 
individuals. It's all in the code. 
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Image provided by Dr. Akiko Shimamura 
Top: pedigree of a family with thrombocytopenia and cancer 
predisposition. Bottom: positions of germline and somatic mutations 
in ETV6, relative to the PNT oligomerization and ETS DNA-binding 
domains. Red highlights indicate germline alterations reported in 
this study. Somatic mutations described in the literature include 
alterations associated with a range of malignancies, as indicated. 
 
